Smith & Nephew Plc SN. Directorate Change

  Smith & Nephew Plc (SN.) - Directorate Change

RNS Number : 4318R
Smith & Nephew Plc
19 November 2012




                                      

                                      

                                      

       Julie Brown Appointed Chief Financial Officer



19 November 2012





Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology
business, today announces the appointment of Julie Brown as Chief Financial
Officer. She will formally take up the post by early February 2013, when she
will also be appointed to the Board as an Executive Director.



Julie joins from AstraZeneca PLC, where she served as Vice President Group
Finance and recently as Interim Chief Financial Officer. In her 25 years with
AstraZeneca (and predecessor companies) she has held a number of senior
financial and management positions including Regional Vice President Latin
America, Marketing Company President AZ Portugal and Vice President Corporate
Strategy and Research and Development Chief Financial Officer.



She qualified as a Chartered Accountant with KPMG and is a Fellow of the
Institute of Chartered Accountancy and a Fellow of the Institute of Taxation.
Julie is a British national. 



Olivier Bohuon, Chief Executive Smith & Nephew, commented:



"Julie is an outstanding leader who brings to Smith & Nephew exceptional
financial expertise and a deep knowledge of the healthcare market. Her
ability to build teams and her broad experience working across geographies and
within senior commercial roles will undoubtedly enable her to be a strong
business partner. I look forward to working closely together as we continue to
reshape Smith & Nephew for future success."



Julie Brown commented:



"I am excited to be joining Smith & Nephew with the Company at such an
important point in its development, and I am looking forward to working
alongside Olivier and the entire Smith & Nephew team."

No disclosure obligations arise under paragraphs (1) to (6) of LR 9.6.13 R of
the UK Listing Authority's Listing Rules in respect of this appointment.

Enquiries



Investors

Phil Cowdy
Tel: +44 (0) 20 7401 7646

Smith & Nephew



Media

Charles Reynolds Tel:
+44 (0) 20 7401 7646

Smith & Nephew



Justine McIlroy / Andrew Mitchell Tel: +44 (0) 20 7404
5959

Brunswick - London





About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping
improve people's lives. With leadership positions in Orthopaedic
Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith &
Nephew has almost 11,000 employees and a presence in more than 90 countries.
Annual sales in 2011 were nearly $4.3 billion. Smith & Nephew is a member of
the FTSE100 (LSE: SN, NYSE: SNN).



Forward-looking Statements

This document may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth and
trading margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate",
"well-placed", "believe", "estimate", "expect", "target", "consider" and
similar expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual results to
differ materially from what is expressed or implied by the statements. For
Smith & Nephew, these factors include: economic and financial conditions in
the markets we serve, especially those affecting health care providers, payors
and customers; price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals, reimbursement
decisions or other government actions; product defects or recalls; litigation
relating to patent or other claims; legal compliance risks and related
investigative, remedial or enforcement actions; strategic actions, including
acquisitions and dispositions, our success in integrating acquired businesses,
and disruption that may result from changes we make in our business plans or
organisation to adapt to market developments; and numerous other matters that
affect us or our markets, including those of a political, economic, business
or competitive nature. Please refer to the documents that Smith & Nephew has
filed with the U.S. Securities and Exchange Commission under the U.S.
Securities Exchange Act of 1934, as amended, including Smith & Nephew's most
recent annual report on Form 20-F, for a discussion of certain of these
factors.



Any forward-looking statement is based on information available to Smith &
Nephew as of the date of the statement. All written or oral forward-looking
statements attributable to Smith & Nephew are qualified by this caution. Smith
& Nephew does not undertake any obligation to update or revise any
forward-looking statement to reflect any change in circumstances or in Smith &
Nephew's expectations.









                     This information is provided by RNS
           The company news service from the London Stock Exchange

END


BOAGCBDBLUBBGDC -0- Nov/19/2012 13:00 GMT